Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B1532

Sigma-Aldrich

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

Synonym(s):

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H13NO3
CAS Number:
87687-02-3
Molecular Weight:
303.31
MDL number:
MFCD00171613
UNSPSC Code:
12352204
PubChem Substance ID:
24891597
NACRES:
NA.32

product name

Resorufin benzyl ether, CYP450 substrate

Quality Level

200

Assay

≥98% (TLC)

form

powder

solubility

chloroform: 9.80-10.20 mg/mL, clear, orange

storage temp.

2-8°C

SMILES string

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2

InChI key

XNZRYTITWLGTJS-UHFFFAOYSA-N

Substrates

Fluorimetric substrate for cytochrome P450-linked enzymes.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Proadifen hydrochloride analytical standard, ≥95%

Supelco

P1061

Proadifen hydrochloride

Seth Kwabena Amponsah et al.
Evidence-based complementary and alternative medicine : eCAM, 2020, 7956493-7956493 (2020-07-28)
There is considerable evidence that many patients concurrently administer dietary supplements with conventional drugs, creating a risk for potential drug-supplement interaction. The aim of this study was to determine the effect of Cellgevity® supplement on selected rat liver cytochrome P450
Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
R W Nims et al.
The Journal of pharmacology and experimental therapeutics, 270(1), 348-355 (1994-07-01)
To explore further the structural requirements for ligand interaction with the putative phenobarbital receptor, the pharmacodynamics of CYP2B induction by 5,5-diphenylbarbituric acid, phenytoin (5,5-diphenylhydantoin), barbital (5,5-diethylbarbituric acid) and 5,5-diethylhydantoin were investigated in the male F344/NCr rat. Steady-state total (free plus
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
Nantana Nuchtavorn et al.
Analytica chimica acta, 1098, 86-93 (2020-01-18)
Cytochrome P450 (CYP450), and in particular CYP3A4, is the most abundantly expressed CYP450 isozyme implicated in many drug-drug and medicinal plant-drug interactions. Therefore, incorporation of CYP3A4 enzyme screening at an early stage of drug discovery is preferable in order to
View All Related Papers

Articles

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I Drug Metabolism

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service